Dalekos G N, Achenbach K, Christodoulou D, Liapi G K, Zervou E K, Sideris D A, Tsianos E V
Department of Internal Medicine, Gastroenterology, School of Medicine, University of Ioannina, Greece.
Heart. 1998 Sep;80(3):270-5. doi: 10.1136/hrt.80.3.270.
To determine whether there is an association between hepatitis C virus (HCV) infection and dilated cardiomyopathy in a well defined area of north western Greece; such an association has been reported elsewhere.
Evaluation of consecutive patients with chronic HCV infection for the presence of clinical or subclinical manifestations of dilated cardiomyopathy by history, physical examination, and non-invasive laboratory procedures (ECG, chest x ray, and echocardiography) before the initiation of interferon alpha treatment; investigation for HCV infection markers in patients with dilated cardiomyopathy by enzyme and immunoblot assays (antibodies to HCV) and the reverse transcriptase polymerase chain reaction (HCV RNA).
A tertiary referral centre for patients with chronic hepatitis and dilated cardiomyopathy.
102 patients with well defined chronic HCV infection and 55 patients with well established dilated cardiomyopathy were evaluated.
The need for HCV testing in patients with dilated cardiomyopathy, or follow up for heart disease in patients with chronic HCV infection.
None of the patients with chronic HCV infection had clinical or subclinical evidence of dilated cardiomyopathy from history and laboratory findings. None of the patients with dilated cardiomyopathy was positive for antibodies to HCV or viraemic on HCV RNA testing.
The study neither confirms the findings of other investigators, nor indicates a pathogenic link between HCV and dilated cardiomyopathy. For this reason, at least in Greece, testing for HCV in patients with dilated cardiomyopathy or follow up for heart disease in HCV patients appears unnecessary. Genetic or other factors could be the reason for this discrepancy if previously reported associations between HCV and dilated cardiomyopathy or hypertrophic cardiomyopathy were not coincidental.
确定在希腊西北部一个明确界定的地区,丙型肝炎病毒(HCV)感染与扩张型心肌病之间是否存在关联;其他地方已有此类关联的报道。
在开始使用α干扰素治疗前,通过病史、体格检查及非侵入性实验室检查(心电图、胸部X线及超声心动图),对连续的慢性HCV感染患者进行评估,以确定是否存在扩张型心肌病的临床或亚临床症状;通过酶联免疫吸附试验和免疫印迹法(抗HCV抗体)以及逆转录聚合酶链反应(HCV RNA),对扩张型心肌病患者进行HCV感染标志物检测。
一家慢性肝炎和扩张型心肌病患者的三级转诊中心。
对102例明确诊断为慢性HCV感染的患者和55例确诊为扩张型心肌病的患者进行了评估。
扩张型心肌病患者进行HCV检测的必要性,或慢性HCV感染患者进行心脏病随访的必要性。
根据病史和实验室检查结果,慢性HCV感染患者均无扩张型心肌病的临床或亚临床证据。扩张型心肌病患者的抗HCV抗体检测或HCV RNA病毒血症检测均为阴性。
该研究既未证实其他研究者的发现,也未表明HCV与扩张型心肌病之间存在致病联系。因此,至少在希腊,对扩张型心肌病患者进行HCV检测或对HCV患者进行心脏病随访似乎没有必要。如果先前报道的HCV与扩张型心肌病或肥厚型心肌病之间的关联并非偶然,那么遗传或其他因素可能是造成这种差异的原因。